Latest Content

Dr. Miguel Gonzales-Velez explains how placebos are used in phase 3 cancer trials, and why joining one does not mean giving up standard treatment.

Medicare will narrow ostomy suppliers to about eight national contracts, and advocate Ellyn Mantell says a poor fit can put patients in the hospital.

Prostate cancer treatment has advanced rapidly in five years. Explore key FDA approvals, improved treatments and what these changes mean for patients.

FDA grants accelerated approval to Hyrnuo (sevabertinib) for certain patients with HER2-mutated, advanced or metastatic non-small cell lung cancer.

The FDA has withdrawn its accelerated approval of Krazati combined with Erbitux for adults with KRAS G12C-mutated colorectal cancer that is locally advanced or has spread to other parts of the body.

Dr. Diego Schaps discussed how upcoming Medicare competitive bidding changes could affect access to ostomy supplies and why having the right pouching system matters for patients.

Dr. Andrew Ip answers common lymphoma questions, from diagnosis and treatment options to CAR T-cell therapy, side effects and hope for patients.

Bristol Myers Squibb reports positive results from a phase 2 trial of investigational CAR T-cell therapy arlo-cel in relapsed multiple myeloma.

Hargitay shared her thoughts with CURE regarding her father’s journey, her motivation for speaking out now, and the key message she wants to convey to patients today.

Cancer survivor Brynn Forlizzi and caregiver Teddy Aaron created Soothe Note, an app designed to help cancer patients and caregivers manage care.

My multiple myeloma nurse case manager sat in on every appointment, helped me appeal an insurance denial and made sure I never felt like just a number.

Dr. Doured Daghistani discusses how childhood cancer treatment, survivorship care and immunotherapy have evolved this Childhood Cancer Awareness Month.

My daughter was 27 when breast cancer forced a decision about her fertility in days, and I keep thinking about the young women who can't afford that choice.